Award details

Development of epidermicin NI01 for nasal decolonization

Reference	BB/J021474/1
Principal Investigator / Supervisor	Professor Mathew Upton
Co-Investigators / Co-Supervisors	Professor Jeremy Paul Derrick, Dr Peter Warn
Institution	The University of Manchester
Department	Medical and Human Sciences
Funding type	Research
Value (£)	132,497
Status	Completed
Type	Research Grant
Start date	01/10/2012
End date	31/03/2014
Duration	18 months

Abstract

unavailable

Summary

The World Health Organisation have stated that infections caused by antibiotic resistant bacteria (e.g. MRSA) are one of the greatest current threats to public health and there is an urgent need for novel antibiotics to combat drug resistant infections. We have discovered epidermicin, an exciting and important new antibiotic that rapidly kills MRSA and other bacteria. The new antibiotic is more active than current antibiotics, is non-toxic and bacteria don't develop resistance to it. These are significant advantages over current antibiotics so we plan to develop epidermicin for clinical use. People who carry MRSA in the nose have a high risk of developing infection and transmitting MRSA, so we will examine how effective epidermicin is for removing MRSA from the nose. We will also carry out experiments designed to help us to understand how epidermicin kills bacteria and why they do not become resistant and carry out work to ensure that the antibiotic is not toxic when used clinically.

Committee	Not funded via Committee
Research Topics	Immunology, Microbiology, Pharmaceuticals, Structural Biology
Research Priority	X – Research Priority information not available
Research Initiative	Follow-On Fund (FOF) [2004-2015]
Funding Scheme	X – not Funded via a specific Funding Scheme

I accept the terms and conditions of use (opens in new window)

export PDF file

back to list new search